Starling Oncology, Inc.

STLN Healthcare Medical Care Facilities

Starling Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.7 million, up 27.8% from fiscal 2024. In the quarter to June 2026, revenue grew 34.6%, EPS grew 46.7%, free cash flow grew 196.7% and total debt rose 6.46%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

6.43 0.48 −6.95%
Market cap
$690.9M
P/E
0.0×
Fwd P/E
−32.5×
Dividend yield
—
F-score
4/9
Altman Z
1.42
Beneish M
−3.39
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

4 4 4 5
ROE
(4,132.17%) 999.19% 775.91% 214.12%
ROA
(38.67%) (35.93%) (26.19%) (21.47%)
ROIC
(70.85%) (80.21%) (63.75%) (117.66%)
Return on Tangible Assets
(120.02%) (115.51%) (90.26%) (81.31%)
Average Days of Receivables
47.48 43.07 39.76 41.46
Free Cash Flow per Share
(0.28) (0.30) (0.25) (0.03)
Free Cash Flow
(27.53) (27.79) (25.73) (3.29)
Capital Expenditures
(3.89) (3.20) (3.91) (3.61)
Other line items
Cash ROIC
(30.06%) (29.17%) (27.78%) (3.42%)
Accounts Receivable Turnover
8.03 9.31 10.00 9.58
Accounts Payable Turnover
13.05 12.63 12.04 10.40
Inventory Turnover
27.10 31.68 25.32 27.66
Average Days of Payables
33.12 36.96 37.54 44.44
Days of Inventory on Hand
17.55 14.45 19.14 14.75
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
22.21% 21.00% 19.86% 18.98%
Share Based Compensation of Revenue
0.98% 0.91% 0.88% 0.87%
Interest Coverage
(3.90) (3.20) (4.28) (3.42)
Operating CF/Net income
0.36 0.41 0.50 (0.01)
Depreciation/Fixed assets
1.47 1.43 1.07 1.10
Capex/Depreciation
(0.25) (0.21) (0.34) (0.31)
Revenue per Share
4.73 5.44 5.36 5.70
Operating CF per Share
(0.24) (0.27) (0.21) 0.00
Capex per Share
(0.04) (0.03) (0.04) (0.04)
Capex to Sales
0.01 0.01 0.01 0.01

Fold the line items

Columns are period end dates